Search and Browse
Download
Enter Data
| Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348611 (US10577374, Compound 334 | US9790229, Compound 334) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet  | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348612 (US10577374, Compound 335 | US9790229, Compound 335) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348624 (US10577374, Compound 347 | US9790229, Compound 347) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348632 (US10577374, Compound 355 | US9790229, Compound 355) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348637 (US10577374, Compound 360 | US9790229, Compound 360) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348389 (US10577374, Compound 112 | US9790229, Compound 112) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348390 (US10577374, Compound 113 | US9790229, Compound 113) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348412 (US10577374, Compound 135 | US9790229, Compound 135) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid PDB UniChem | PDB US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair |  3D Structure (crystal) | ||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348424 (US10577374, Compound 147 | US9790229, Compound 147) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348427 (US10577374, Compound 150 | US9790229, Compound 150) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348428 (US10577374, Compound 151 | US9790229, Compound 151) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348429 (US10577374, Compound 152 | US9790229, Compound 152) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348596 (US10577374, Compound 319 | US9790229, Compound 319) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348599 (US10577374, Compound 322 | US9790229, Compound 322) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348618 (US10577374, Compound 341 | US9790229, Compound 341) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348327 (US10577374, Compound 50 | US9790229, Compound 50) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348387 (US10577374, Compound 110 | US9790229, Compound 110) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348388 (US10577374, Compound 111 | US9790229, Compound 111) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348562 (US10577374, Compound 285 | US9790229, Compound 285) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348591 (US10577374, Compound 314 | US9790229, Compound 314) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348593 (US10577374, Compound 316 | US9790229, Compound 316) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348606 (US10577374, Compound 329 | US9790229, Compound 329) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348616 (US10577374, Compound 339 | US9790229, Compound 339) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348555 (US10577374, Compound 278 | US9790229, Compound 278) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348560 (US10577374, Compound 283 | US9790229, Compound 283) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348582 (US10577374, Compound 305 | US9790229, Compound 305) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348584 (US10577374, Compound 307 | US9790229, Compound 307) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348585 (US10577374, Compound 308 | US9790229, Compound 308) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348589 (US10577374, Compound 312 | US9790229, Compound 312) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348594 (US10577374, Compound 317 | US9790229, Compound 317) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348627 (US10577374, Compound 350 | US9790229, Compound 350) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348629 (US10577374, Compound 352 | US9790229, Compound 352) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348323 (US10577374, Compound 46 | US9790229, Compound 46) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348384 (US10577374, Compound 107 | US9790229, Compound 107) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348430 (US10577374, Compound 153 | US9790229, Compound 153) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348433 (US10577374, Compound 156 | US9790229, Compound 156) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348554 (US10577374, Compound 277 | US9790229, Compound 277) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348578 (US10577374, Compound 301 | US9790229, Compound 301) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348588 (US10577374, Compound 311 | US9790229, Compound 311) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348600 (US10577374, Compound 323 | US9790229, Compound 323) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348601 (US10577374, Compound 324 | US9790229, Compound 324) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348604 (US10577374, Compound 327 | US9790229, Compound 327) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348621 (US10577374, Compound 344 | US9790229, Compound 344) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348625 (US10577374, Compound 348 | US9790229, Compound 348) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348634 (US10577374, Compound 357 | US9790229, Compound 357) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348636 (US10577374, Compound 359 | US9790229, Compound 359) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348329 (US10577374, Compound 52 | US9790229, Compound 52) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348386 (US10577374, Compound 109 | US9790229, Compound 109) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348425 (US10577374, Compound 148 | US9790229, Compound 148) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM348583 (US10577374, Compound 306 | US9790229, Compound 306) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US9790229 (2017) BindingDB Entry DOI: 10.7270/Q22809RK | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Displayed 1 to 50 (of 360 total ) | Next | Last >> |
